Cost Effectiveness Analysis of Vaborem in Carbapenem-Resistant Infections: A Comprehensive Review

Joan Aug 11, 2026

Overview of Cost Effectiveness Analysis Of Vaborem In Carbapenem Resistant

SECTION 3 Carbapenem resistant Enterobacterales CRE Malaysian
SECTION 3 Carbapenem resistant Enterobacterales CRE Malaysian

Vaborem is a fixed dose combination of vaborbactam and meropenem with potent activity against target Carbapenem-resistant Enterobacterales (CRE) pathogens, optimally developed for Klebsiella pneumoniae carbapenemase (KPC). The study aims to evaluate ...

PDF Cost effectiveness analysis of Vaborem in Carbapenem resistant
PDF Cost effectiveness analysis of Vaborem in Carbapenem resistant

Background Vaborem is a fixed dose combination of vaborbactam and meropenem with potent activity against target Carbapenem-resistant Enterobacterales (CRE) pathogens, optimally developed for Klebsiella pneumoniae carbapenemase (KPC). The study aims to evaluate the cost-effectiveness of Vaborem versus best available therapy (BAT) for the treatment of patients with CRE-KPC associated infections ...

Key Details About Cost Effectiveness Analysis Of Vaborem In Carbapenem Resistant

The most common multidrug resistant isolates ESBL Extended spectrum
The most common multidrug resistant isolates ESBL Extended spectrum

The study objective of this analysis was to determine the cost-effectiveness of vaborem (meropenem-vaborbactam) compared to the best available therapy (BAT) in adult patients with carbapenem-resistant Enterobacteriaceae—Klebsiella pneumoniae ...

Conclusion Due to a limited cost impact and increase in patient quality of life, vaborem can be considered as a cost -effective treatment option compared to BAT for adult patients with CRE-KPC infections in the UK. Keywords Meropenem-vaborbactam • Carbapenem-resistant Enterobacteriaceae - Klebsiella pneumoniae carbapenemase •

PDF Prevalence and factors associated with carbapenem resistant
PDF Prevalence and factors associated with carbapenem resistant

Useful Notes on Cost Effectiveness Analysis Of Vaborem In Carbapenem Resistant

The study objective of this analysis was to determine the cost-effectiveness of vaborem (meropenem-vaborbactam) compared to the best available therapy (BAT) in adult patients with carbapenem-resistant Enterobacteriaceae— Klebsiella pneumoniae carbapenemase (CRE-KPC) infections from the perspective of the UK National Health Service (NHS) and ...

Abstract Background: Vaborem is a fixed dose combination of vaborbactam and meropenem with potent activity against target Carbapenem-resistant Enterobacterales (CRE) pathogens, optimally developed for Klebsiella pneumoniae carbapenemase (KPC). The study aims to evaluate the cost-effectiveness of Vaborem versus best available therapy (BAT) for the treatment of patients with CRE-KPC associated ...

Carbapenem Resistant E Coli K Pneumoniae and Other Enterobacterales
Carbapenem Resistant E Coli K Pneumoniae and Other Enterobacterales

Overview of Cost Effectiveness Analysis Of Vaborem In Carbapenem Resistant

Vaborem is a fixed dose combination of vaborbactam and meropenem with potent activity against target Carbapenem-resistant Enterobacterales (CRE) pathogens, optimally developed for Klebsiella pneumoniae carbapenemase (KPC). The study aims to evaluate the cost-effectiveness of Vaborem versus best ...

The study aims to evaluate the cost-effectiveness of Vaborem versus best available therapy (BAT) for the treatment of patients with CRE-KPC associated infections in the Italian setting.

Flow diagram illustrating the breakdown of carbapenem resistant
Flow diagram illustrating the breakdown of carbapenem resistant

Key Details About Cost Effectiveness Analysis Of Vaborem In Carbapenem Resistant

Cost-effectiveness analysis of vaborem for the treatment of carbapenem-resistant Enterobacteriaceae-Klebsiella pneumoniae carbapenemase (CRE-KPC) infections in the UK April 2022

Carbapenem Resistant Enterobacterales CREs Nurseslab
Carbapenem Resistant Enterobacterales CREs Nurseslab
Carbapenemase Producing Carbapenem Resistant Enterobacterales CP CRE
Carbapenemase Producing Carbapenem Resistant Enterobacterales CP CRE
Carbapenem Resistant Enterobacterales and the key to rapid phenotypic
Carbapenem Resistant Enterobacterales and the key to rapid phenotypic
Carbapenem Resistant Enterobacterales CRE
Carbapenem Resistant Enterobacterales CRE
Carbapenem Resistant Enterobacteriaceae CRE
Carbapenem Resistant Enterobacteriaceae CRE

The study objective of this analysis was to determine the cost-effectiveness of vaborem (meropenem-vaborbactam) compared to the best available therapy (BAT) in adult patients with carbapenem-resistant Enterobacteriaceae-Klebsiella pneumoniae carbapenemase (CRE-KPC) infections from the perspective of the UK National Health Service (NHS) and ...